Table 1.
Characteristics of the included studies
| Author | Year | Country | Design | Treatment duration | Number of participants | Total Number of Patients | Diagnostic Criteria | Female (%) | Age (years) | MMF Dose (mg/day) | |
|---|---|---|---|---|---|---|---|---|---|---|---|
| MMF + Pred | AZA + Pred | ||||||||||
| Dalekos et al. [21] | 2022 | Greece | Prospective propensity matching trial | 3–5 years | 32 | 32 | 64 | IAIHG | 71.90% | 54.5 | 1500–2000 |
| Dalekos et al. [23] | 2022 | Greece | Prospective cohort study | 50 months | 183 | 64 | 247 | IAIHG | 73.27% | 50 | 1500–2000 |
| Hlivko et al. [18] | 2008 | USA | Retrospective cohort study | 13 months | 16 | 85 | 101 | AASLD | 83% | 42.8 | 500–2000 |
| Snijders et al. [19] | 2024 | Netherlands + Belgium | RCT | 24 weeks | 39 | 31 | 70 | IAIHG | 72.90% | 57.9 | 1000–2000 |
| Zachou et al. [15] | 2016 | Greece | Prospective cohort study | 72 months | 109 | 22 | 131 | IAIHG | 73.40% | 47.5 | 1500–2000 |
Abbreviations: AASLD American association for the study of liver diseases, AZA Azathioprine, IAIHG International autoimmune hepatitis group, MMF Mycophenolate Mofetil, Pred Prednisolone, RCT randomized controlled trial